


Partnership opportunities with Sanofi Pasteur

Sanofi Pasteur, the vaccines division of Sanofi, is seeking partners who will share the company's pursuit of innovation and drive for excellence. Our diverse culture and geography allow us to collaborate effectively with a broad array of partners around the world.

We are not only at the forefront of conquering newly targeted infectious diseases, but also leading the way in expanding immunization across all age groups, including adolescents and the elderly. This leadership has translated into outstanding success in the industry, and our company has experienced a recent period of unprecedented growth.

Sanofi Pasteur is interested in partners who will share in the pursuit of innovation and our drive for excellence, while becoming a part of our market success story. "We welcome the opportunity to evaluate technologies related



3D model of Dengue virus capsid structure

Sanofi Pasteur is improving global human health by discovering, developing, manufacturing, and supplying vaccines for the prevention and treatment of infectious diseases.

Sanofi Pasteur is interested in potential partnering opportunities in the field of active and passive human immunization, as well as technologies supporting product development and industrial performance, including:

Vaccines, monoclonal antibodies and supporting technologies for prevention and treatment of infectious diseases

- Novel antigens and methods for antigen discovery and characterization
- Vaccine vectors suitable for nasal or oral use
- New ways to administer vaccines
- Carrier proteins and protein-polysaccharide conjugation methods or alternative technologies

Agents to enhance vaccine immune responses

- Adjuvants and immunomodulators
- Vaccine vectors and delivery systems intended to enhance or modify immune responses
- Biological and immunological studies to further characterize adjuvants and immunomodulators

Characterization and assay of immune responses and disease markers

- Animal models of human diseases
- *In vitro* models of human tissues, including the immune system
- Biological markers for evaluating the efficacy of prophylactic or therapeutic interventions
- Epidemiological studies relevant to the use of vaccines and immunotherapeutics

Tools for improving vaccine and monoclonal antibody research, development and production

- Development and application of new technologies in the areas of genomics and proteomics
- Downstream processing, purification and aseptic filling processes
- Prokaryotic or eukaryotic cell lines for antigen production
- Process automation
- Fermentor and bioreactor technology
- Preservatives and stabilizers
- Disposable systems
- Bioinformatics techniques for modeling, data handling and analysis
- Online testing
- Anti-counterfeiting technology

to the development and production of human vaccines, both prophylactic and therapeutic, including vaccines for infectious and chronic diseases," said Jeffrey Almond, PhD.

Sanofi Pasteur has a strong commitment to Research and Development partnerships with major universities, research institutes, government bodies, biotechnology companies and contract research organizations. The company's collaborations cover virtually all aspects of vaccine development, including early-stage research.

Examples of current partnerships and technology investments include: vaccines for dengue fever, Japanese encephalitis, *S. pneumoniae*, and *M. tuberculosis*; pediatric combination vaccines; rabies monoclonal antibodies; large-scale, cell culture-based virus production; adjuvants and immunomodulators; conjugate vaccine production; and vaccine delivery systems.

A company partnering with Sanofi Pasteur interacts with a multidisciplinary team that has years of experience in working to ensure that partnerships are executed successfully and nurtured for the mutual benefit of all parties.

This approach utilizes the value-added Sanofi

Pasteur alliance management capability, which focuses on the relationship by facilitating open communication, trust, understanding and clear expectations across the project lifespan. Combined with the technical competency of the alliance, this balance provides a well rounded environment for your technology to flourish.

CONTACT DETAILS

Sanofi Pasteur welcomes information about new partnership opportunities. Each opportunity is carefully evaluated and reviewed by our dedicated team.

Please contact:

Jeffrey Almond, PhD

Vice President, Discovery and External Research and Development

Tel: +33 4 3737 9453

Email: jeffrey.almond@sanofipasteur.com

Jean-Marc Renard, MS, MBA

Vice President, Corporate Development

Tel: +33 4 3737 3480

Email: jean-marc.renard@sanofipasteur.com